Vast signs additional partners for commercial space station microgravity research
AI-summarised brief · reviewed before publication
Vast, a commercial space station company, announced the addition of several partners for microgravity research and manufacturing, including the Sanford Stem Cell Institute, Auxilium Biotechnologies, LambdaVision, and BioOrbit. The partnerships, established through memoranda of understanding, aim to continue research done on the International Space Station after its retirement. The agreements cover potential future use of Vast's space stations for microgravity research and related projects, focusing on biomedical research and applications. Vast's partners have previously conducted research on the ISS, with LambdaVision testing artificial retina production and Auxilium Biotechnologies producing implantable medical devices. The partnerships will help advance discoveries in space-based manufacturing and biotechnology, building on the legacy of the ISS. Vast's Haven stations will provide a platform for continued research, enabling the development of new technologies and treatments.
💡 Why It Matters
- · The partnerships bring together leaders in biotechnology and space research, accelerating the development of innovative treatments and technologies.
- · By leveraging microgravity environments, these collaborations can lead to breakthroughs in disease modeling and regenerative medicine.